About Protein N-terminal asparagine amidohydrolase
Protein N-terminal asparagine amidohydrolase (NTAN1) is a protein
from Homo sapiens identified by UniProt accession
Q96AB6, 310 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Protein N-terminal asparagine amidohydrolase |
| UniProt accession | Q96AB6 |
| Gene | NTAN1 |
| Organism | Homo sapiens |
| Length | 310 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (138)
Diseases linked to this target (Open Targets).
- phosphatidylcholine measurement · score 0.45
- triglyceride measurement · score 0.43
- body height · score 0.41
- cholesteryl ester 20:3 measurement · score 0.39
- blood metabolite measurement · score 0.39
- high density lipoprotein cholesterol measurement · score 0.37
- sex hormone-binding globulin measurement · score 0.37
- omega-6 polyunsaturated fatty acid measurement · score 0.37
- lean body mass · score 0.36
- body mass index · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96AB6-F1 | alphafold | PREDICTED | 95.61 | — |
Amino-acid sequence (310 residues)
MPLLVEGRRV RLPQSAGDLV RAHPPLEERA RLLRGQSVQQ VGPQGLLYVQ QRELAVTSPK DGSISILGSD DATTCHIVVL RHTGNGATCL THCDGTDTKA EVPLIMNSIK SFSDHAQCGR LEVHLVGGFS DDRQLSQKLT HQLLSEFDRQ EDDIHLVTLC VTELNDREEN ENHFPVIYGI AVNIKTAEIY RASFQDRGPE EQLRAARTLA GGPMISIYDA ETEQLRIGPY SWTPFPHVDF WLHQDDKQIL ENLSTSPLAE PPHFVEHIRS TLMFLKKHPS PAHTLFSGNK ALLYKKNEDG LWEKISSPGS
Explore Protein N-terminal asparagine amidohydrolase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets